Clinical Trials on Total Hip Replacement System in Japan

Total 50 results

Sanofi

Completed

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Arthroplasty, Replacement, Hip

Japan
Yokohama City University Medical Center

Unknown

The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA) (ETOD)

Arthroplasty, Replacement, Hip | Bone Density

Japan
Zimmer Biomet
Biomet Japan, Inc.

Completed

Review on Minimally Invasive Skin Incision in Vanguard PS Artificial Knee Joint System

Gonarthrosis Patients Who Need Artificial Knee Joint Total Replacement

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Embolism and Thrombosis | Thrombosis | Deep Vein Thrombosis | Thromboembolism | Venous Thromboembolism | Arthroplasty, Replacement, Hip

Japan, Taiwan
Shinshu University

Recruiting

Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA

Hip OA

Japan
Aesculap AG

Completed

Non-Interventional, Multicenter Bicontact® E PMCF Study

Rheumatoid Arthritis | Femoral Neck Fractures | Femoral Head Necrosis | Degenerative Osteoarthritis

Japan
National University Hospital, Singapore

Recruiting

The Southeast and East Asian Post-Operative Delirium (SEAPOD) Study

Postoperative Delirium | Hip Fractures

Singapore, Japan, Korea, Republic of, Malaysia, Thailand
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Completed

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

HIV Infections

Japan
National Center for Global Health and Medicine,...
Ministry of Health, Labour and Welfare, Japan

Unknown

HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation (HIV-ABMi)

HIV Infection | Cirrhosis | AIDS

Japan
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Completed

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

HIV Infection

Japan
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
GlaxoSmithKline

Completed

Pharmacokinetic Study Of EPZICOM Tablet

HIV Infection

Japan
National Center for Global Health and Medicine,...
Ministry of Health, Labour and Welfare, Japan

Completed

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (SPARE)

HIV Infections

Japan
National Center for Global Health and Medicine,...

Completed

Safety Study of Maraviroc's Effect on Human Osteoclasts (MVC-Bone)

HIV Infections | AIDS

Japan
Abbott

Completed

Special Investigation of Kaletra in Pregnant Women

Human Immunodeficiency Virus

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Muscle Wasting (Atrophy) After Hip Fracture Surgery

Colombia, Belgium, Hungary, Taiwan, Spain, Czechia, United States, France, Germany, Turkey, Japan, Russian Federation, United Kingdom, Argentina, Australia, Mexico, Chile, Switzerland, Austria
Yale University
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Not yet recruiting

Developing a Chatbot to Promote HIV Testing

HIV Infections

Malaysia
Kirby Institute
Pfizer; ViiV Healthcare

Completed

Maraviroc Switch Collaborative Study (MARCH)

HIV

Spain, Australia, Ireland, Mexico, Germany, Argentina, Canada, Chile, France, Japan, Poland, Thailand, United Kingdom
Abbott

Completed

Drug Use Investigation of Kaletra

Human Immunodeficiency Virus

Japan
Kirby Institute

Completed

MARCH Renal Substudy (MARCHrenal)

Proteinuria | HIV

Canada, Australia, Germany, Argentina, Japan, Thailand, United Kingdom, Mexico
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
AbbVie (prior sponsor, Abbott)

Completed

Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection

Human Immunodeficiency Virus Infection

Japan
Gilead Sciences

Completed

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

HIV | HBV

United States, Canada, Japan
Merck Sharp & Dohme LLC

Active, not recruiting

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

HIV-1 Infection

United States, Australia, Chile, Israel, Japan, United Kingdom
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

HIV-1 Infection

United States, Australia, Canada, Colombia, Japan, South Africa, Switzerland, United Kingdom
National Institute of Allergy and Infectious Diseases...
Chiron Corporation

Completed

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (ESPRIT)

HIV Infections

United States, Brazil, Australia, Argentina, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Morocco, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, Thailand, United Kingdom
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Pfizer

Completed

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

Chronic Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Korea, Republic of, Taiwan, Australia, Serbia, Japan, New Zealand, Philippines, Lithuania, Russian Federation, Croatia, Brazil, Bulgaria, Slovakia, Colombia, Mexico, Peru, Ukraine
AbbVie

Recruiting

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human Immuno-deficiency Virus (HIV) Disease

United States, Puerto Rico, Japan, Spain, Germany, Canada, Belgium, France, Poland, South Africa, Italy
Gilead Sciences

Recruiting

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

HIV-1-infection

Japan, Germany, France, United States, Spain, Korea, Republic of, South Africa, Australia, Argentina, Canada, Dominican Republic, Italy, Puerto Rico, Taiwan, United Kingdom
ViiV Healthcare

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOGUE)

HIV Infections | HIV

Spain, Poland, France, Israel, Belgium, Portugal, Germany, Italy, Argentina, Greece, Japan, Ireland, Switzerland, United Kingdom, Denmark, Sweden, Mexico
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

HIV-1 Infection

United States, Argentina, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, South Africa, Spain, Taiwan
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Spain, Switzerland, Canada, Thailand, Puerto Rico, Australia, Austria, Belgium, Italy, Japan, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

HIV-1 Infection

United States, Israel, Puerto Rico, Japan, South Africa, Chile, Thailand, United Kingdom, Argentina, Colombia, France, Germany, Malaysia, Spain, Switzerland, Guatemala, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

HIV Infection

United States, Australia, Austria, Canada, Finland, France, Germany, Italy, Japan, Puerto Rico, Spain
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

HIV Infection

United States, Australia, Canada, Chile, Colombia, France, Italy, Japan, New Zealand, Poland, Russian Federation, South Africa, Spain, Switzerland, United Kingdom
National Institute of Allergy and Infectious Diseases...
Community Programs for Clinical Research on AIDS

Completed

Collection of Blood Samples From SMART Study Participants for Future Genetic Studies

HIV Infections

United States, New Zealand, Australia, Japan, American Samoa, Belgium, Canada, Chile, Denmark, Finland, Gambia, Germany, Morocco, Poland, Portugal, Uruguay
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

HIV Infection

United States, Russian Federation, Argentina, Australia, Canada, Chile, Colombia, Israel, Japan, New Zealand, Puerto Rico, South Africa, Switzerland, Taiwan, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (Alliance)

HIV-1/HBV Co-Infection

Spain, Taiwan, Korea, Republic of, Thailand, Hong Kong, Japan, France, Turkey, Puerto Rico, Malaysia, United States, China, Dominican Republic, Greece
Merck Sharp & Dohme LLC

Active, not recruiting

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, New Zealand, Poland, Russian Federation, South Africa, Spain, Switzerland, United Kingdom
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
ViiV Healthcare
GlaxoSmithKline

Completed

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

United States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
Alnylam Pharmaceuticals

Completed

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Acute Hepatic Porphyria | Acute Intermittent Porphyria | Porphyria, Acute Intermittent | Acute Porphyria | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP)

United States, Spain, United Kingdom, Korea, Republic of, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Sweden, Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

HIV Infections

United Kingdom, Argentina, Switzerland, France, Brazil, United States, Estonia, Spain, Australia, Peru, Austria, Belgium, Canada, Germany, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Martinique, New Zealand, Norway, Poland, Puerto... and more
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Shionogi

Completed

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens (CREDIBLE - CR)

Sepsis | Bloodstream Infections (BSI) | Hospital Acquired Pneumonia (HAP) | Complicated Urinary Tract Infection (cUTI) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)

United States, Brazil, Croatia, France, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United Kingdom

Clinical Trials on Total Hip Replacement System in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations